Percheron Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PER.AX research report →
Price Chart
About the company
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma.
- CEO
- James Garner
- IPO
- 2023
- Employees
- 8
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on PER.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.13M
- P/E
- -1.34
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.00
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -65.33%
- ROIC
- -64.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-219,565-223.0%
- Op Income
- $-5,620,004
- Net Income
- $-4,791,745+67.9%
- EPS
- $-0.00+71.9%
- OCF Growth
- +68.3%
- FCF Growth
- +68.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.03
- RSI (14)
- 61
- Avg Volume
- 4.10M
No earnings-call transcripts are available for PER.AX yet.
- Free Float
- 76.6%
- Shares Outstanding
- 1.11B
- Float Shares
- 852.91M
Our PER.AX coverage
Recent articles, reports, and earnings notes.
No research on PER.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PER.AX report →Percheron Therapeutics Phase II progress highlighted by Edison with 5.5-cent valuation
proactiveinvestors.com · Aug 5
Provaris Energy advances hydrogen and CO₂ shipping technologies during June quarter
proactiveinvestors.com · Jul 31
American Rare Earths advances Halleck Creek feasibility and pilot plant plans in pivotal June quarter
proactiveinvestors.com · Jul 31
archTIS caps record FY2026 quarter with ARR surge and defence momentum
proactiveinvestors.com · Jul 31
St George Mining accelerates Araxá development after strong June quarter
proactiveinvestors.com · Jul 31
Noble Helium strengthens balance sheet and advances Kinambo drilling during June quarter
proactiveinvestors.com · Jul 31
Percheron Therapeutics targets clinical return for HMBD-002 after productive June quarter
proactiveinvestors.com · Jul 31
Altech Batteries sharpens CERENERGY focus after securing grant extension in June quarter
proactiveinvestors.com · Jul 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.